skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Evaluation of degarelix in the management of prostate cancer

Review

(4359) Views  (1258) Full article downloads

Authors: Hendrik Van Poppel

Published Date January 2010 Volume 2010:2 Pages 39 - 52
DOI: http://dx.doi.org/10.2147/CMAR.S8841

Hendrik Van Poppel

Department of Urology, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium

Abstract: Medical castration using gonadotropin-releasing hormone (GnRH) receptor agonists currently provides the mainstay of androgen deprivation therapy for prostate cancer. Although effective, these agents only reduce testosterone levels after a delay of 14 to 21 days; they also cause an initial surge in testosterone that can stimulate the cancer and lead to exacerbation of symptoms (“clinical flare”) in patients with advanced disease. Phase III trial data for the recently approved GnRH receptor blocker, degarelix, demonstrated that it is as effective and well tolerated as GnRH agonists. However, it has a pharmacological profile more closely matching orchiectomy, with an immediate onset of action and faster testosterone and PSA suppression, without a testosterone surge or microsurges following repeated injections. As a consequence, with this GnRH blocker, there is no risk of clinical flare and no need for concomitant antiandrogen flare protection. Degarelix therefore provides a useful addition to the hormonal armamentarium for prostate cancer and offers a valuable new treatment option for patients with hormone-sensitive advanced disease. Here, we review key preclinical and clinical data for degarelix, and look at patient-focused perspectives in the management of prostate cancer.

Keywords: degarelix, GnRH receptor antagonist, GnRH receptor blocker, prostate cancer








Readers of this article also read:

Periosteoplasty for covering gingival recessions: Clinical results
Degarelix and its therapeutic potential in the treatment of prostate cancer
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Optimal management of cancer anorexia–cachexia syndrome
Rituximab for the treatment of patients with chronic lymphocytic leukemia
Study of pharmacokinetics and tissue distribution of liposomal brucine for dermal administration
Perception of risk and benefit in patient-centered communication and care
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University